Haemonetics Corporation (HAE)

Return on total capital

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	164,883	170,195	167,496	178,925	156,033	139,977	132,349	110,127	80,750	40,376	45,150	79,422	89,747	136,929	137,411	128,368	103,351	101,200	88,613	64,950
Long-term debt	US$ in thousands	797,564	856,849	748,662	751,381	754,102	756,826	759,552	763,141	559,441	633,118	698,043	767,345	690,592	292,721	297,016	296,893	305,513	309,738	313,984	318,144
Total stockholders’ equity	US$ in thousands	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569	587,109	574,580	583,754	590,966
Return on total capital		9.38%	9.45%	10.20%	11.07%	9.93%	9.13%	8.89%	7.18%	6.17%	2.96%	3.23%	5.50%	6.31%	13.53%	14.24%	14.18%	11.58%	11.44%	9.87%	7.14%

March 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $164,883K ÷ ($797,564K + $959,959K)
= 9.38%

Haemonetics Corporation's return on total capital has experienced fluctuations over the past several quarters. The return on total capital ranged from a low of 2.96% in March 2022 to a high of 14.24% in December 2020.

Overall, the return on total capital has shown an upward trend in recent quarters, with a slight decrease in the most recent quarter to 9.38%. This indicates that the company is generating a positive return relative to the total capital invested in the business.

It is important for investors and stakeholders to monitor this ratio to assess the efficiency of the company in generating returns from its total capital. The company's ability to maintain or improve its return on total capital over time can signify effective capital allocation and operational performance.